BRCA1 and ovarian carcinoma: In the context of BRCA1-mutated breast and ovarian cancers, ELC exhibited selective sensitivity to cancer cells with mutant BRCA1 and showed synergistic effects when combined with DNA-damaging agents or PARP inhibitors [78].